Seth Richards

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

More From Seth Richards

• 

  .

  Company & Industry Overviews

  Measuring Mylan’s Biggest Risks Moving Forward

  Aside from the risky generic pharmaceutical industry, Mylan faces company-specific business risks like country risk, foreign exchange risk, and M&A risk.

• 

  .

  Company & Industry Overviews

  Mylan’s Recent Acquisitions Continue to Strengthen Its Position in International Markets

  Mylan takes an M&A strategy to save time related to compliance activities for obtaining regulatory approvals across various international markets.

• 

  .

  Company & Industry Overviews

  Gauging Mylan’s Aggressive Acquisition Strategy

  By acquiring UDL Laboratories, Mylan entered the unit dose and the long-term care market. In 1998, Mylan added Penederm to its dermatological division.

• 

  .

  Company & Industry Overviews

  How Has Manufacturing Its Own Active Pharmaceutical Ingredients Helped Mylan?

  Mylan is one of largest API (active pharmaceutical ingredient) manufacturers in the world, with nine API and intermediate manufacturing facilities.

• 

  .

  Company & Industry Overviews

  Mylan Product Portfolio across Key Therapeutic Areas

  Mylan is a leading pharmaceutical company that operates in more than 140 countries and operates across five different therapeutic areas.

• 

  .

  Company & Industry Overviews

  Sizing up Mylan’s Blockbuster Drugs: Perforomist, Ultiva, and Emsam

  Mylan NV is the generic drug leader in the US prescription drug market with blockbuster drugs such as Perforomist, Ultiva, and Emsam.

• 

  .

  Company & Industry Overviews

  Assessing the Role of the EpiPen Auto-Injector in Mylan’s Revenues

  Used to deliver Epinephrine in the treatment of severe allergic reactions, Mylan’s EpiPen auto-injectors hold the number one rank in the epinephrine market.

• 

  .

  Company & Industry Overviews

  Mylan’s Business Model: A Key Investor Rundown

  In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.

• 

  .

  Company & Industry Overviews

  Locating Mylan’s Geographic Market Strategy

  Compared to peers Teva Pharmaceuticals, Valeant Pharmaceuticals, and Zoetis, Mylan earns substantially higher revenues from the US generic market.

• 

  .

  Company & Industry Overviews

  Introducing Mylan, a Big International Gun in Generic Pharmaceuticals

  Headquartered in the UK, Mylan is one of the biggest players in the generic pharmaceutical industry. It was founded by Milan Puskar and Don Panoj in 1961.